BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4

• Press Releases

  ONWARD Medical Announces First Implant in New Clinical Feasibility Study Evaluating ARC-IM System to Restore Mobility After Spinal Cord Injury

  September 3, 2026

   · 

  5 min read
• Press Releases

  Sensorion Announces Approval of Clinical Trial Application in France for SENS-601, Its Investigational Gene Therapy for the Treatment of GJB2-Related Hearing Loss

  September 3, 2026

   · 

  9 min read
• Press Releases

  Egetis Therapeutics to Participate in Upcoming Investor Conferences in September 2026

  September 3, 2026

   · 

  5 min read
• Press Releases

  Nxera Pharma to Receive $8.6 Million Milestone Payment from Centessa Pharmaceuticals Following Late-stage Development Progress

  September 3, 2026

   · 

  3 min read
• Press Releases

  IRLAB’s CEO Intends to Step Down During the First Quarter of 2027

  September 3, 2026

   · 

  2 min read
• Press Releases

  Chiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are Validated

  September 3, 2026

   · 

  7 min read
• Press Releases

  Biodesix to Participate in Upcoming September 2026 Investor Conferences

  September 3, 2026

   · 

  1 min read
• Press Releases

  Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026

  September 3, 2026

   · 

  13 min read
• Press Releases

  ANI Pharmaceuticals to Present at September 2026 Investor Conferences

  September 3, 2026

   · 

  1 min read
• 

  Rare diseases

  Ultragenyx’s ‘high-risk’ Angelman bet fails, cratering stock and forcing strategic review

  The success of apazunersen in a Phase 3 trial for Angelman syndrome was a key driver of Ultragenyx’s value, according to William Blair, and the asset’s failure robs the biotech of any meaningful near-term milestones.

  September 3, 2026

   · 

  2 min read

   · 

  Tristan Manalac